Rapid Micro Biosystems (RPID) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $6.6 million, up 32% year-over-year, marking a record quarter and exceeding guidance.

• Net loss narrowed to $12.6 million ($0.29/share) from $14.0 million ($0.33/share) in Q2 2023.

• Five Growth Direct Systems were placed globally, including the 150th system and the first Rapid Sterility System.

• Operational Efficiency Program launched, targeting $7 million in annual savings and positive cash flow by end of 2027 without additional financing.

• Strong customer engagement and multi-system order discussions are ongoing, with a growing installed base and product adoption.

Financial highlights

• Product revenue rose 43% to $4.5 million; service revenue increased 14% to $2.1 million.

• Recurring revenue grew 7% to $3.8 million; nonrecurring revenue surged 97% to $2.8 million.

• Gross margin improved to -3% from -38% year-over-year; product margin improved 40 percentage points to -8%.

• Cash, cash equivalents, and investments totaled approximately $70 million as of June 30, 2024, with no debt.

• Operating expenses totaled $13.2 million (flat year-over-year in some reports), with R&D and S&M up 15% and G&A down 14%.

Outlook and guidance

• Full-year 2024 revenue expected to be at least $27 million, implying 20%+ growth and at least 20 system placements.

• Q3 revenue expected at least $6 million, with 4 system placements; Q4 expected to be the strongest quarter.

• Gross margins expected to turn positive in Q3 and Q4, and for the full year.

• Operating expenses for 2024 guided at $48–$52 million, with $7 million in annual savings from efficiency program.

• Positive cash flow targeted by end of 2027, assuming mid-20s to 30% annual revenue growth and improving gross margins.